Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | AHR | P35869 | 1/20 | 0.58 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | HTR6 | P50406 | 3/20 | 0.56 |
| ▸ | HTR1D | P28221 | 2/20 | 0.56 |
| ▸ | HTR1B | P28222 | 2/20 | 0.56 |
| ▸ | HTR2A | P28223 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | MPO | P05164 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9161488 | 0.84 | MEN1 (0.65) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL29376364 | 0.82 | MAPT (0.68) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL40822 | 0.82 | MAPT (0.68) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL3262116 | 0.82 | MAPT (0.68) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL6873654 | 0.82 | MEN1 (0.58) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL4598405 | 0.81 | MAPT (0.66) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL30295582 | 0.81 | MAPT (0.66) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL837741 | 0.79 | MEN1 (0.55) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| Indole-3-Acetic Acid SCHEMBL2269865 | 0.79 | MAPT (0.69) | MEN1KMT2AMAPTALDH1A1KDM4E | |
| SCHEMBL874981 | 0.79 | MEN1 (0.55) | MEN1KMT2AMAPTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101801961-B | Pyrrolidinone, pyrrolidine-2, 5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | ARQULE INC | 2014-09-24 | — | — | CN | disclosed |
| EP-2170870-B1 | PYRROLIDINONE, PYRROLIDINE-2, 5-DIONE, PYRROLIDINE AND THIOSUCCINIMIDE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE INC (US) | 2014-03-05 | — | — | EP | disclosed |
| EP-2170870-B1 | PYRROLIDINONE, PYRROLIDINE-2, 5-DIONE, PYRROLIDINE AND THIOSUCCINIMIDE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE INC (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8304425-B2 | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304425-B2 | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304425-B2 | Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer | ARQULE, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| CN-101801961-A | Pyrrolidone, tetramethyleneimine-2,5-diketone, tetramethyleneimine and thiosuccimide derivative, composition and treatment method for cancer | ARQULE INC | 2010-08-11 | — | — | CN | disclosed |
| US-20100178291-A1 | Pyrrolidinone, Pyrrolidine-2, 5-Dione, Pyrrolidine and Thiosuccinimide Derivatives, Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178291-A1 | Pyrrolidinone, Pyrrolidine-2, 5-Dione, Pyrrolidine and Thiosuccinimide Derivatives, Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100178291-A1 | Pyrrolidinone, Pyrrolidine-2, 5-Dione, Pyrrolidine and Thiosuccinimide Derivatives, Compositions and Methods for Treatment of Cancer | ARQULE, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| EP-2170870-A1 | PYRROLIDINONE, PYRROLIDINE-2, 5-DIONE, PYRROLIDINE AND THIOSUCCINIMIDE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ArQule, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009002806-A1 | PYRROLIDINONE, PYRROLIDINE-2, 5-DIONE, PYRROLIDINE AND THIOSUCCINIMIDE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002806-A1 | PYRROLIDINONE, PYRROLIDINE-2, 5-DIONE, PYRROLIDINE AND THIOSUCCINIMIDE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER | ARQULE, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178291-A1 | Pyrrolidinone, Pyrrolidine-2, 5-Dione, Pyrrolidine and Thiosuccinimide Derivatives, Compositions and Methods for Treatment of Cancer | PYCR1, DHPS, TYMP | MEN1 2360/4885KMT2A 2078/4885MAPT 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.